8-K: Capricor Therapeutics Announces Positive Data and Financial Results for 2024, BLA Accepted for Priority Review

Capricor Therapeutics reports FDA acceptance of its BLA for deramiocel with priority review, positive clinical data, and a strong cash position to support operations into 2027.

Summary

• Capricor Therapeutics announced its fourth quarter and full year 2024 financial results and provided a corporate update.
• The FDA accepted Capricor's Biologics License Application (BLA) for deramiocel for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy and granted it priority review with a PDUFA target action date of August 31, 2025.
• Positive data from the HOPE-2 open label extension (OLE) trial showed a 52% slowing of disease progression over three years.
• Capricor received a $10 million milestone payment from Nippon Shinyaku.
• The company's cash balance was approximately $151.5 million at the end of 2024, expected to support current planned operations into 2027.
• Fourth quarter revenues were $11.1 million, and full year revenues were $22.3 million.
• The net loss for the fourth quarter was $7.1 million, or $0.16 per share, and the net loss for the full year was $40.5 million, or $1.15 per share.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with FDA acceptance of the BLA, promising clinical data, a strong cash position, and regulatory designations in Europe. While there are reported net losses, the overall tone is optimistic due to the potential for deramiocel to address an unmet medical need.

Positives

• FDA acceptance of the BLA with priority review signifies a major regulatory milestone for deramiocel.
• Positive HOPE-2 OLE trial data demonstrates the potential long-term therapeutic durability of deramiocel, with a 52% slowing of disease progression.
• The $10 million milestone payment from Nippon Shinyaku strengthens Capricor's financial position.
• A strong cash balance of $151.5 million provides financial runway into 2027.
• EMA Orphan Drug and ATMP designations offer benefits such as market exclusivity and regulatory support in Europe.
• Selection of the StealthX vaccine to be part of Project NextGen.

Negatives

• The company reported a net loss of $7.1 million for the fourth quarter of 2024, compared to a net loss of $0.8 million for the fourth quarter of 2023.
• The company reported a net loss of $40.5 million for the year ended December 31, 2024, compared to a net loss of $22.3 million for the year ended December 31, 2023.
• Total operating expenses increased to $64.8 million for the year ended December 31, 2024, compared to $49.3 million for the year ended December 31, 2023.

Risks

• The success of deramiocel is contingent on FDA approval, which is not guaranteed.
• Clinical trials may not continue to produce positive results.
• The company's financial outlook depends on maintaining its current operating plan and financial resources.
• Reliance on Nippon Shinyaku for commercialization and distribution introduces partnership risks.
• The biotechnology industry is subject to rapid technological change and intense competition.

Future Outlook

Capricor believes its current cash, cash equivalents, and marketable securities will be sufficient to cover anticipated expenses and capital requirements into 2027, excluding potential milestone payments from Nippon Shinyaku and any strategic use of capital not currently in the company's base-case planning assumptions.

Management Comments

• Linda Marbn, Ph.D., Chief Executive Officer of Capricor, stated that 2024 was a transformational year as they move closer to bringing the first cellular therapy to market for DMD cardiomyopathy.
• Dr. Marbn noted that the company ended the year with over $150 million on its balance sheet, allowing them to invest in manufacturing expansion and commercial endeavors.

Industry Context

Capricor's focus on DMD cardiomyopathy addresses a significant unmet need, as there are currently no approved therapies for this condition. The BLA acceptance and priority review from the FDA position Capricor as a potential leader in the development of cell-based therapies for rare diseases. The company's exosome-based approach also aligns with the growing interest in exosomes as therapeutic delivery vehicles.

Comparison to Industry Standards

• Capricor's deramiocel is competing in the DMD treatment landscape, which includes companies like Sarepta Therapeutics (SRPT) with gene therapies and PTC Therapeutics (PTCT) with small molecule drugs.
• The 52% slowing of disease progression observed in the HOPE-2 OLE trial is a clinically meaningful outcome that compares favorably to other treatments in development.
• Capricor's cash runway into 2027 provides a competitive advantage compared to smaller biotech companies that may need to raise capital more frequently.
• The EMA's Orphan Drug and ATMP designations are similar to those granted to other companies developing therapies for rare diseases, providing regulatory and commercial benefits.

Stakeholder Impact

• Shareholders will benefit from the potential approval and commercialization of deramiocel.
• Patients with DMD cardiomyopathy may have a new treatment option available.
• Employees will be involved in the manufacturing and commercialization of deramiocel.
• Nippon Shinyaku will benefit from the commercialization and distribution of deramiocel in the United States and Japan.

Next Steps

• Capricor will continue to work towards the August 31, 2025 PDUFA action date for deramiocel.
• The company will prepare for pre-approval licensure inspection and potential commercial launch with Nippon Shinyaku.
• Capricor plans to present at upcoming industry conferences.
• The National Institute of Allergy and Infectious Diseases (NIAID) is planning for regulatory approval of StealthX vaccine in the second quarter of 2025 with the clinical study initiated soon thereafter.

Key Dates

Keywords

deramiocel, Duchenne muscular dystrophy, DMD, cardiomyopathy, Biologics License Application, BLA, FDA, Nippon Shinyaku, cell therapy, exosomes, StealthX, clinical trial, financial results